Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Obesity drugs clinical pipeline U.S. 2018, by type and phase

Clinical pipeline for obesity drugs in the U.S. as of 2018, by type and phase

by Matej Mikulic, last edited Apr 18, 2019
Obesity drugs clinical pipeline U.S. 2018, by type and phase This statistic depicts the number of the clinical pipeline for novel obesity drugs based on number of drug programs as of September 2018, by type and phase. According to the data, there were 12 phase I chemical trials for novel chemicals with new MOAs.
Show more

Clinical pipeline for obesity drugs in the U.S. as of 2018, by type and phase

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.
Dr. Horst Stipp

Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation

Statistics on "Diabetes in the U.S."
  • Overview
The most important statistics
  • Cases
  • Prevalence
  • Hospitalizations
  • Deaths
  • Comorbidities
  • Obesity
  • Miscellaneous
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.